Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Blinatumomab

EU orphan designation number: EU/3/09/650   
Active ingredient: Blinatumomab
Indication: Treatment of acute lymphoblastic leukaemia
Sponsor: Amgen Europe B.V.
Minervum 7061, NL-4817 ZK Breda, Nederland

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
30/07/2009 Centralised Orphan - Designation EMEA/OD/029/09 (2009)6042 of 24/07/2009
31/01/2012 Other procedure EMEA/OD/029/09
19/06/2012 Other procedure EMEA/OD/029/09
17/02/2014 Centralised Orphan - Transfer of orphan designation EMEA/OD/029/09/T/01 (2014)1082 of 13/02/2014